Beijing News Beike Finance News on August 19, Kangchen Pharmaceutical announced that its income for six months ended on June 30, 2025 ended RMB 1.569 billion, an increase of nearly 23.7% over the six months ended on June 30, 2024. For six months ended June 30, 2025, the income related to the equity shaaranders of the company is the company's equity shareless. 2024年6月30日止于六个月内六个月内的4.98亿元人民币，24.6％。